Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 11Withdrawn 2Terminated 2Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Prostatic Neoplasms 25Breast Neoplasms 19Multiple Myeloma 17Neoplasm Metastasis 15Lung Neoplasms 15Ovarian Neoplasms 14Lymphoma 14Glioma 14Carcinoma, Renal Cell 14Carcinoma, Non-Small-Cell Lung 12Pancreatic Neoplasms 11Fallopian Tube Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 9Sarcoma 9Medulloblastoma 9Cholangiocarcinoma 9Neuroblastoma 8Glioblastoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Thyroid Neoplasms 7Oropharyngeal Neoplasms 7Uterine Cervical Neoplasms 6Rhabdoid Tumor 6Rectal Neoplasms 6Neuroendocrine Tumors 6Mouth Neoplasms 6Lymphoma, Non-Hodgkin 6

Interventions

Rituximab 23Cyclophosphamide 15ibrutinib 14acalabrutinib 13CT-P10 10venetoclax 8Lenalidomide 8Bendamustine Hydrochloride 8fludarabine 7Cytarabine 6fludarabine phosphate 5zanubrutinib 4obinutuzumab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4pirtobrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Etoposide 3palbociclib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2brexucabtagene autoleucel 2auricularum 2Vincristine 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Mantle-Cell × Magnetic Resonance Spectroscopy × Clear all
NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡